Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bisoprolol for prevention of subclinical heart failure during cancer therapy
IRCT20240609062050N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Apr 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of bisoprolol in Anthracycline Cardiomyopathy and heart failure (HF) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Left ventricular diastolic function, Left ventricular systolic function and 1 more. Started Apr 2022; status: completed.
02
Drugs
bisoprolol
03
Conditions
Anthracycline Cardiomyopathyheart failure (HF)
Beyond the preview
Go deeper on IRCT20240609062050N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240609062050N1.